Skip to main content

Table 1 Baseline characteristics of training and validation groups

From: A nomogram to predict conversion of laparoscopic surgery to laparotomy for Choledocholithiasis

Variables

Whole group

(n = 867)

Training group

(n = 607)

Validation group

(n = 260)

P value

Age [year]

   

0.051

  ≤ 60

347(40.0)

240(39.5)

107(41.2)

 

 60 ~ 80

459(52.9)

332(54.7)

127(48.8)

 

 >80

61(7.0)

35(5.8)

26(10.0)

 

Sex

   

0.910

 Male

386(44.5)

271(44.6)

115(44.2)

 

 Female

481(55.5)

336(55.4)

145(55.8)

 

BMI [Kg/m2]

   

0.545

  < 24

565(65.2)

389(64.1)

176(67.7)

 

 24 ~ 28

249(28.7)

181(29.8)

68(26.2)

 

  > 28

53(6.1)

37(6.1)

16(6.2)

 

Diabetes

114(13.1)

85(14.0)

29(11.2)

0.274

Hypertension

265(30.6)

183(30.1)

82(31.5)

0.684

PUAS

147(17.0)

103(17.0)

44(16.9)

> 0.95

History of ERCP

45(5.2)

29(4.8)

16(6.2)

0.406

Pancreatitis

55(6.3)

33(5.4)

22(8.5)

0.097

WBC[*109/L]

   

0.370

  ≤ 10

787(90.8)

547(90.1)

240(92.3)

 

  > 10

80(9.2)

60(9.9)

20(7.7)

 

ALB [g/L]

   

0.428

  ≤ 35

231(26.6)

157(25.9)

74(28.5)

 

  > 35

636(73.4)

450(74.1)

186(71.5)

 

TBIL [μmol/L]

   

0.683

  ≤ 17.1

411(46.1)

285(47.0)

126(48.5)

 

  > 17.1

456(53.9)

322(53.0)

134(51.5)

 

ALP [U/L]

   

0.421

  ≤ 125

260(30.0)

187(30.8)

73(28.1)

 

  > 125

607(70.0)

420(69.2)

187(71.9)

 

ALT [U/L]

   

0.421

  ≤ 40

243(28.0)

175(28.8)

68(26.2)

 

  > 40

624(72.0)

432(71.2)

192(73.8)

 

AST [U/L]

   

0.582

  ≤ 40

312(36.0)

222(36.6)

90(34.6)

 

  > 40

555(64.0)

385(63.4)

170(65.4)

 

GGT [U/L]

   

0.374

  ≤ 50

138(15.9)

101(16.6)

37(14.2)

 

  > 50

729(84.1)

506(83.4)

223(85.8)

 

Maximum diameter of CBD stone [mm]

   

0.518

  < 12

563(64.9)

390(64.3)

173(66.5)

 

  ≥ 12

304(35.1)

217(35.7)

87(33.5)

 

CBD stone’s location

    

Duodenal upper segment

   

0.620

 Yes

181(20.9)

124(20.4)

57(21.9)

 

 No

686(79.1)

483(79.6)

203(78.1)

 

Duodenal posterior segment

   

0.470

 Yes

331(38.2)

227(37.4)

104(40.0)

 

 No

536(61.8)

380(62.6)

156(60.0)

 

Pancreatic segment

   

0.566

 Yes

635(73.2)

448(73.8)

187(71.9)

 

 No

232(26.8)

159(26.2)

73(28.1)

 

Medial wall of the duodenum

   

0.887

 Yes

62(7.2)

43(7.1)

19(7.3)

 

 No

824(92.8)

564(92.9)

241(92.7)

 

The number of stones in CBD

   

0.880

 Negative/sludge

33(3.8)

24(4.0)

9(3.5)

 

 Single

384(44.3)

266(43.8)

118(45.4)

 

 Multiple

450(51.9)

317(52.2)

133(51.2)

 

IHD stone

   

0.466

 Yes

156(18.0)

113(18.6)

43(16.5)

 

 No

711(82.0)

494(81.4)

217(83.5)

 

Thickening of gallbladder wall

321(37.0)

230(37.9)

91(35.0)

0.419

Thickening of CBD wall

63(7.3)

44(7.2)

19(7.3)

> 0.95

Diameter of CBD

13.3(10.7,17.0)

13.9(11.0,17.0)

13.0(10.0,16.1)

0.120

Stone size/CBD size

   

0.190

  < 0.75

424(48.9)

288(47.4)

136(52.3)

 

  ≥ 0.75

443(51.1)

319(52.6)

124(47.7)

 

Surgery method

    

 Conversion to laparotomy

151(17.4)

102(16.8)

49(18.8)

0.468

Simultaneous LC

   

0.442

 Yes

754(87.0)

524(86.3)

230(88.5)

 

 No

113(13.0)

83(13.7)

30(11.5)

 

Simultaneous LH

   

0.426

 Yes

91(10.5)

67(11.0)

24(9.2)

 

 No

776(89.5)

540(89.0)

236(90.8)

 

Laser lithotripsy

19(2.2)

12(2.0)

7(2.7)

0.613

  1. Data are expressed as n (%) unless otherwise specified
  2. BMI body mass index, PUAS previous upper abdominal surgery, ERCP endoscopic retrograde cholangiopancreatography, WBC white blood cell, ALB albumin total bilirubin, TBIL total bilirubin, ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, GGT gamma-glutamyl transpeptidase, CBD common bile duct, IHD intrahepatic bile duct, LC laparoscopic cholecystectomy, LH laparoscopic hepatectomy